The European Federation of Pharmaceutical Industries and Associations’ new medicines verification system will put an end to the re-sale of stolen and counterfeit drugs in the European supply chain, the organisation claims.
The European Federation of Pharmaceutical Industries and Associations’ new medicines verification system will put an end to the re-sale of stolen and counterfeit drugs in the European supply chain, the organisation claims.
The European Stakeholder Model (ESM) reportedly offers a cost-effective technological solution using anti-tampering device together with 2D barcoding to verify the authenticity of medicinal products.
Because of loopholes in traceability systems across EU jurisdictions, stolen medicines are re-entering the legal trade in EU countries through fictitious or corrupt brokers. With EFPIA’s verification system, serial numbers corresponding to each packaging will be recorded in the system; in case of repackaging, a link between the originators’ serial numbers and the traders’ serial numbers at batch level will be secured in the system. This link, reports EFPIA, will prevent any re-introduction of stolen medicines on any EU markets.
Last week AIFA, the Italian Medicines Agency, reported that between 2006 and 2013 one in ten Italian hospitals registered thefts of pharmaceuticals.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.